Dr. Rüdiger Herrmann is an EMEA lead of our Life Sciences Group and a partner in the Corporate Practice based in the Frankfurt office. He focuses his practice on key transactions in the biotechnology and pharmaceutical sectors.

He has a wealth of experience advising national and international clients on mergers and acquisitions, licensing agreements, initial public offerings, intellectual property matters and private equity/venture capital transactions.

He has a particularly strong background in dealing with life science matters in the US, Europe, China and Taiwan.

Rüdiger regularly speaks on biotechnology, pharmaceuticals, private equity and M&A topics, having lectured at Bio International, Bio Europe, Bio Equity and the Venture Capital forum in London, among other conferences.

Award Mouse thought multimedia interface book medal screen monitor
  • Advised a Swedish listed biotech company on the negotiation of an exclusive licence agreement regarding the development and commercialisation of its antibody product by a US company in China, Taiwan, Hong Kong and Macau.
  • Advised a German listed biotech company on the global restructuring of its manufacturing and supply relationships, including the negotiation of a commercial manufacturing and supply agreement with its API supplier, as well as corresponding supply agreements with its third-party customers.*
  • Advised a German nutraceutical company on its corporate reorganisation, as well as on a global manufacturing and supply agreement with a US customer.
  • Advised an Austrian listed biotech company on the negotiation of a clinical supply agreement with a global biopharma company ancillary to an existing collaboration and licence agreement.*
  • Advised a listed Polish biotec company on a global collaboration and licence agreement with a Dutch biotec partner. The agreement for the global development of fibrotic drugs included various collaboration and licensing aspects, as well as a right of first refusal for Galapagos. GDPR issues also needed to be spe¬cifically addressed.
  • Advised an Austrian listed biotech company on a global licence agreement with a Swiss university.*
  • Advised a German cell therapy company on establishing an intra-group master services and supply agreement and other related agreements.*
  • Advised a Swiss biotech company on a collaboration and licence agreement with a Benelux biotech company involving the algorithm-based identification and selection of patient-individual tumour-specific drug targets.*
  • Advised a German listed biotech company on the negotiation of a global licence and co-development agreement for its lead compound and various ancillary agreements, including a development supply agreement and a manufacture licence and tech transfer agreement.*
  • Advised a Polish client on a global licence agreement with an Italian pharma company.
  • Represented a German listed company in one of the first licence and global co-development deals between a Chinese pharma company and a Western company. The transaction included licensing and co-development aspects, as well as an equity component. Highly complex transaction regarding regulatory, financial and development arrangements.
  • Advised a German biotech company on a licence and cooperation agreement with a world-leading diagnostics company.*
  • Advised a Polish biotec company on the launch of a joint venture subsidiary, which was co-financed by a European venture fund.*
  • Advised a listed European/US-based biotec company on an exclusive strategic collaboration with one of the leading US pharma companies.*
  • Advised a German biotec company on a licensing and co-development partnership for its lead compound with an Italian pharma company.*
  • Advised a German biotec company on a licensing and development partnership for a cancer compound with a Chinese biotec company.*
  • Advised a Dutch biotech company on a commercialisation agreement for gene therapy product and a co-development agreement with an Italian pharma company.*
  • Represented a Canada-based biotech company in a licence and equity investment transaction with a Chinese publicly listed company regarding the licensing of its platform technology for cardiovascular and metabolic diseases.*
  • Advised a leading German medical and pharmaceutical device company on its joint venture project in the Middle East and Russia.*
  • Advised a Germany-based animal health company on its joint venture and licence transaction with a China-based animal health company.*
  • Represented a listed German company in its cross-border licensing transaction with a China-based pharmaceutical company.*

* Matter handled prior to joining the firm.

Education

  • Higher Regional Court of Mainz, Second State Examination, 1995
  • University of Hagen, Dr. Jur., (PhD), 1994
  • University of Mainz, First State Examination, 1992

Admissions

  • Germany, 1996

Memberships and Affiliations

  • Member of BayHelix
  • Member of the Advisory Board of Impact Hub
  • German Association for Intellectual Property and Copyright Law
  • German-French Lawyers’ Association
  • German-American Lawyers’ Association
  • German Lawyers’ Association

Languages

  • German
  • English
  • French
  • Recommended as one of the best lawyers for biotechnology law and life sciences practice in Germany by Handelsblatt (Deutschlands beste Anwälte 2022) and Best Lawyers.
  • Recommended by Handelsblatt/Best Lawyers 2021, Germany, Lawyer of the Year in Biotechnology and Life Sciences.
  • Recognised by Who's Who Legal 2014-2020 as a leading attorney for life sciences in Germany and referred to as “a top transactional lawyer” and “super negotiator”.
  • Recommended by Leaders League's 2019 Guide for Innovation, Technology & Patents, and awarded Excellent in the Health, Pharma & Biotechnology category.
  • Recommended in the JUVE Handbuch der Wirtschaftskanzleien 2018/2019 for M&A. 
  • Chambers & Partners 2019, Life Sciences, Germany, Volume 3.
  • Recommended as one of the leading lawyers in The Legal 500 EMEA 2019
  • Recommended by Expert Guides ranking Best of the Best for Life Sciences in Germany.
  • Awarded as Life Sciences Star by LMG Life Sciences Europe 2014.

{{insights.date}} {{insights.type}} {{insights.contentTypeTag}}
Award Mouse thought multimedia interface book medal screen monitor